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Dermatofibrosarcoma protuberans yra itin retas vaikų piktybinis navikas. Nurodoma, kad klasikinė dermatofibrosarkomos for-
ma labai retai metastazuoja, o fibrosarkominei jos transformacijai dažnai būdingos metastazės. Mes aprašome išopėjusios 
dešiniosios šlaunies dermatofibrosarkomos atvejį septyniolikos metų berniukui. Navikas buvo radikaliai pašalintas. Po viene-
rių metų atkryčio nerasta.
Reikšminiai žodžiai: vaikų dermatofibrosarkoma, minkštųjų audinių sarkomos, fibrosarkominė transformacija, chirurginis 
gydymas
Dermatofibrosarcoma protuberans is a very rare malignant neoplasm in children. It is reported that the classic form of dermatofi-
brosarcoma has a very limited metastatic potential, while a fibrosarcomous transformation of dermatofibrosarcoma protuberans 
has a much higher potential. We present a case of a 17-year-old boy with a huge ulcerated mass (17 x 15 cm) on his right thigh. 
At operation, the pathological diagnosis was dermatofibrosarcoma protuberans with a  fibrosarcomous component. All lesions 
were removed by surgical excision with a margin of 1.5 to 3 cm. After one year, there is no evidence of tumor recurrence.
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Introduction
Dermatofibrosarcoma protuberans (DFSP) was first de-
scribed as a distinct clinicopathologic entity in 1924 (1), 
and it was approximately 30 years later when the tumor 
was first described in a child (2). Epidemiology shows 
0.8–4.2 cases per million persons per year and accounts 
for between 2% and 6% of all soft tissue sarcomas (3). 
It is an uncommon malignant neoplasm of the deep 
dermis and subcutaneous tissue, mostly affecting young 
and middle-aged adults (4). Men and women are equally 
affected (5). According to the WHO classification of 
the mesenchymal tumors, DFSP is an intermediate-
grade, locally-agressive tumor which recurs commonly 
but metastasizes very rarely (5). Because of a high local 
recurrence rate, the benchmark of the therapy is a wide 
surgical excision. On the other hand, complete resection 
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carries the risk of a severe mutilation in relatively small 
children (6). 
The alternative treatment options, such as chemo-
therapy or radiotherapy, have only minimal therapeutic 
effects (3). A novel targeted antitumor treatment is 
based on the specific molecular characterization of the 
DFSP. In over 90% of cases there is a 17q22; 22q13 
translocation leading to a constitutive activation of the 
platelet-derived growth factor receptor (PDGFR) fol-
lowed by a continuous stimulation of the tumor cells to 
grow (3, 5, 6). Initial studies with imatinib mesylate, a 
PDGF receptor-specific oral thyrosine kinase inhibitor, 
showed a response rate of 65% in patients with extensive 
local, recurrent or metastatic DFSP (5). 
Case report
A 17-year-old boy had initially presented to a pediatric 
surgeon with a tumor on the proximal part of his right 
thigh. The mass measured 15 by 17 cm. It was irregular 
in form, fairly hard, and the overlying skin was tense 
and ulcerated. 
Figure 1. Anterior contrast-enhanced CT scan shows a su-
perficial soft tissue mass. Nonhomogenuous accumulation of 
contrast can be seen. It does not appear to invade the adjacent 
subcutaneous fat (white arrow)
Figure 2. DFSP: uniform, mildly atypical tumor cells arranged 
in a storiform pattern. Hematoxylin–eosin staining, x200
Figure 3. Fibrosarcomatous transformation of DFSP. Hemato-
xylin–eosin staining, x200
Figure 4. DFSP cells displaying positivity for CD34. x100
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form can transform into fibrosarcomous DFSP (DFSP-
FS), a more aggressive tumor with a higher metastatic 
potential (8) which may require a more intensive treat-
ment approach.
In this age group, there are a number of soft tissue 
neoplasms which can have a similar appearance, loca-
tion and growth type. The most common site of DFSP 
is the limbs (41%) and trunk (39%) (6). However, 
rhabdomyosarcoma is the most common soft tissue 
sarcoma in children (9) and may present on the limbs. 
Furthermore, rhabdomyosarcoma progresses quickly, 
and our patient complained that the mass grew in a 
year. About a quarter of primary leiomyosarcoma occur 
on the lower limbs, but usually they present in younger 
children. These tumors have very different treatment 
options. The decision to operate was based on the local 
growth of the tumor. 
More than 90% of DFSP have a unique translocation 
involving chromosomes 17 and 22. Usually, CD34 is 
one of the most useful stains to differentiate DFSP from 
other soft tissue tumors. In approximately 3.2–15% of 
DFSP the tumor contains a high-grade fibrosarcomous 
component (3) which may present 20% to 80% of the 
tumor mass. These areas usually have a focal or diffuse 
loss of CD34 (10). A biopsy may hit the CD34-negative 
areas and give false negative results for dermatofibrosar-
coma. In these cases, the RT-PCR analysis to determine 
translocation could be useful to diagnose dermatofibro-
sarcoma. 
The primary treatment for DFSP is complete resec-
tion (3). The best method to remove these lesions is the 
Mohs micrographic surgery (1, 3) with a recurrence rate 
of 1.5% (2). In view of the infiltrative nature of DFSP, 
a wide excision (removal of 2–3 cm of uninvolved skin 
and the en bloc removal of the underlying subcutaneous 
tissue and fascia) had been widely accepted as the main 
treatment option (12). Furthermore, the average recur-
rence rate after a wide excision has been reported to be 
8.8% (3). However, in our case, a wide surgical excision 
could cause considerable cosmetic and functional de-
formities. On the other hand, it has been reported that 
using conservative surgical margins the local recurrence 
rate may reach 39.7% (3). Our decision was to excise as 
widely as possible but leaving the least possible cosmetic 
and functional deformity. 
Ultrasound revealed an irregular nonhomogeneous 
tumor with some signs of calcification. A color Dop-
pler showed a good blood flow in the mass. CT clearly 
defined a homogeneous tumor in the dermis and sub-
cutaneous tissue with a local contact to the right gracilis 
muscle (Figure 1). On post contrast CT, the tumor 
showed nonhomogeneous accumulation of contrast.
The potential malignancy of the tumor was predicted 
by its rapid growth, ulceration, and bleeding. The physical 
examination showed that the tumor was in the skin and 
subcutaneous tissue. CT revealed a limited, local growth 
of the tumor. It was decided to remove it surgically. 
A spindle-shaped incision was made. The blood ves-
sels were ligatured, and the mass was removed intact. 
Bone marrow biopsies were taken from both sides of the 
iliac wings to ascertain there were no metastases.
Histologically, the tumor was composed of a fibrous 
and myxoid tissue and variously cellular sheets of 
spindle-shaped cells with eosinophilic cytoplasm and 
uniform elongated nuclei. The tumor showed up to 5 
mitoses per 10 HPF (Figure 2) and had areas with lon-
gitudinal fascicles of atypical spindle cells demonstrating 
more prominent nuclear atypia and mitotic activity: 
up to 10 mitoses per 10 HPF (fibrosarcomatous trans-
formation). (Figure 3). The tumor cells were positive 
for CD34 and negative for heavy caldesmon, EMA, 
keratins, S100 protein, smooth muscle actin, desmin, 
myogenin, and MyoD1. (Figure 4). By RT-PCR analy-
sis, the tumor exhibited t(17;22)(q22;g13) COL1A1/
PDGFB translocation. 
The tumor reached the margin of the surgical exci-
sion. There were no metastases in the bone marrow 
biopsies. After reoperation, the histological examination 
showed no residual tumor.
Discussion
Dermatofibrosarcoma protuberans (DFSP) is a low – in-
termediate – grade cutaneous sarcoma which is rare in 
adults and even less common in children (7). Never-
theless, it is the most frequent skin sarcoma (3). DFSP 
shows a locally invasive and aggressive behavior and has 
a high recurrence rate but a limited metastatic potential 
(1% to 4%) (4, 5). The metastatic potential depends 
on tumor type. Normally, DFSP is considered to be a 
tumor of low-grade malignancy. Rarely, this “classic” 
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However, the postoperative positive surgical margins 
forced us to consider additional treatment options. 
Dermatofibrosarcoma protuberans is a radio-responsive 
tumor. The addition of postoperative radiotherapy re-
duces the risk of local recurrence in patients with narrow 
or positive surgical margins (13). Because of the high 
risk of gonadal dysfunction this treatment option was 
not suitable for our patient.
DFSP with fibrosarcomous transformation is re-
sistant to conventional chemotherapy (3). A limited 
number of studies show that Imatinib mesylate can 
be effective in such cases (3, 5, 6). Unfortunately, our 
clinic is not able to offer this treatment because of its 
high costs. Reoperation was performed, and no residual 
tumor was found. After one year, there is no evidence of 
tumor recurrence.
Conflict of interests 
None of the authors have declared any conflict of in-
terests.
REFERENCES
1. Jafarian F, McCuaig C, Kokta V, et al. Dermatofibrosar-
coma protuberans in childhood and adolescence: report of eight 
patients. Pediatr Dermatol 2008; 25: 317–325.
2. Checketts SR, Hamilton TK, Baughman RD. Congenital 
and childhood dermatofibrosarcoma protuberans: a case report 
and review of the literature. J Am Acad Dermatol 2000; 42: 
907–913.
3. Lemm D, Mügge LO, Mentzel T, et al. Current treatment 
options in dermatofibrosarcoma protuberans. J Cancer Res Clin 
Oncol 2009; 135: 653–665.
4. Suzuki D, Kobayashi R, Yasuda K, et al. Congenital 
Dermatofibrosarcoma Protuberans in a Newborn Infant With a 
Massive Back Tumor: Favorable Effects of Oral Imatinib on the 
Control of Residual Tumor Growth. J Pediatr Hematol Oncol 
2011; 33: 304–306. 
5. Ugurel S., Kortmann R.D., Mohr P., et al. Short German 
guidelines: dermatofibrosarcoma protuberans. J Dtsch Dermatol 
Ges 2008; 6: 17–18.
6. Gooskens SL, Oranje AP, van Adrichem LN, et al. Imatinib 
mesylate for children with dermatofibrosarcoma protuberans 
(DFSP). Pediatr Blood Cancer 2010; 55: 369–373.
7. Marcus JR, Few JW, Senger C, et al. Dermatofibrosarcoma 
protuberans and the Bednar tumor: treatment in the pediatric 
population. J Pediatr Surg 1998; 33: 1811–1814.
8. Bowne WB, Antonescu CR, Leung DH, et al. Dermatofi-
brosarcoma protuberans: A clinicopathologic analysis of patients 
treated and followed at a single institution. Cancer 2000; 88: 
2711–2720.
9. Pinkel D, Pickren J. Rhabdomyosarcoma in children. 
JAMA 1961; 175: 293–298.
10. Abbott JJ, Oliveira AM, Nascimento AG: The prognostic 
significance of fibrosarcomatous transformation in dermatofibro-
sarcoma protuberans. Am J Surg Pathol. 2006; 30: 436–443.
11. Gloster HM Jr. Dermatofibrosarcoma protuberans. J Am 
Acad Dermatol 1996; 35: 355–374.
12. Martin L, Piette F, Blanc P, et al. Clinical variants of the 
preprotuberant stage of dermatofibrosarcoma protuberans. Br J 
Dermatol 2005; 153(5): 932–926.
13. Ballo MT, Zagars GK, Pisters P, et al. The role of radiation 
therapy in the management of dermatofibrosarcoma protuberans. 
Int J Radiat Oncol Biol Phys 1998; 40(4): 823–827.
